PF 07055480

Drug Profile

PF 07055480

Alternative Names: AAV cDNA gene therapy - Sangamo Therapeutics; AAV cDNA hF8 gene therapy; AAV cDNA human Factor 8 gene therapy; AAV Factor 8 cDNA gene therapy; AAV Factor 8 cDNA in vivo gene therapy; PF-07055480; Recombinant AAV2/6 Human Factor 8 Gene Therapy - Sangamo Therapeutics; SB-525; SB-525 cDNA gene therapy

Latest Information Update: 14 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Factor VIII stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemophilia A

Most Recent Events

  • 08 Aug 2018 Preliminary safety and efficacy data from the phase I/II Alta trial in Haemophilia A released by Sangamo Therapeutics
  • 08 Mar 2018 Phase-II clinical trials in Haemophilia A in USA (IV) (Pfizer pipeline, March 2018)
  • 07 Jun 2017 PF 07055480 receives Orphan Medicinal Product status for Haemophilia A in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top